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Atomic absorption spectroscopy (abst) 575
Atrial natriuretic factor
analogs and derivatives (abst) 335, 337
biosynthesis (abst) 339, 344
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urodilation (abst) 1173
Atrial natriuretic peptide
cardiac state in uremics (abst) 1382
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autoregulation in jAA, TGF 1402
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regulation (abst) 339, 361, 386, 395
regulation during CsA therapy (abst) 1188
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cytosolic, acidosis in VSMC (abst) 1597
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pathophysiology (abst) 199
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response of GH and LH (abst) 1602
therapy (abst) 330
tumor markers (abst) 1605
Chronic renal insufficiency
predialysis, EPO therapy (abst) 1178
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